Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

CG Oncology reports positive first results from the CORE-008 Cohort CX Phase 2 trial of cretostimogene with gemcitabine in high-risk NMIBC

by thaan@22fillmore.com | May 15, 2026 | Portfolio News

Ceribell completes commercial launch of seizure monitoring for newborns and children and activates first sites in its delirium detection pilot

by thaan@22fillmore.com | May 11, 2026 | Portfolio News

Mobia Medical prices $150M initial public offering and begins trading on Nasdaq under the ticker MOBI

by thaan@22fillmore.com | May 7, 2026 | Portfolio News

Veradermics announces positive Phase 3 Study 302 topline results for VDPHL01 in male pattern hair loss

by mariel | Apr 27, 2026 | Portfolio News

Mirum Pharmaceuticals announces primary endpoint met in Phase 2b portion of the AZURE-1 Study of brelovitug in chronic hepatitis delta virus

by mariel | Apr 27, 2026 | Portfolio News

BioAge Labs reports positive Phase 1 data for oral NLRP3 inhibitor BGE-102 in people with obesity and elevated inflammation

by thaan@22fillmore.com | Apr 21, 2026 | Portfolio News

Opna Bio receives FDA Fast Track designation for OPN-6602 in relapsed or refractory multiple myeloma

by thaan@22fillmore.com | Apr 15, 2026 | Portfolio News

Viridian Therapeutics reports positive Phase 3 REVEAL-1 results for elegrobart in active thyroid eye disease

by mariel | Mar 30, 2026 | Portfolio News

Kestra Medical Technologies reports third quarter fiscal 2026 results; raises FY2026 revenue guidance to $93M, representing 55% growth vs. FY2025

by mariel | Mar 17, 2026 | Portfolio News

CytomX Therapeutics reports positive Phase 1 data for CX-2051 (Varseta-M) in colorectal cancer

by mariel | Mar 16, 2026 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • X
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer